carbostyril has been researched along with Rhinitis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, DK; Cho, DY; Grayson, JW; Hill, HS; Lim, DJ; Mackey, C; Peña Garcia, JA; Skinner, D; Weeks, CG; Woodworth, BA; Zhang, S | 1 |
| Cho, DY; Hathorne, H; Lampkin, B; McCormick, J; Richman, J; Rowe, SM; Woodworth, BA | 1 |
| King, HC | 1 |
3 other study(ies) available for carbostyril and Rhinitis
| Article | Year |
|---|---|
l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor.
Topics: Aminophenols; Anti-Bacterial Agents; Biofilms; Chronic Disease; Cystic Fibrosis Transmembrane Conductance Regulator; Disease Progression; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Humans; Methionine; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Rhinitis; Sinusitis | 2018 |
Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminophenols; Child; Chronic Disease; Cohort Studies; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Female; Humans; Male; Mental Health; Middle Aged; Mutation; Prospective Studies; Quality of Life; Quinolones; Rhinitis; Sinusitis; Sleep; Surveys and Questionnaires; Young Adult | 2019 |
Mast cell stabilizers.
Topics: Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Cromolyn Sodium; Humans; Mast Cells; Nedocromil; Quinolones; Rhinitis | 1992 |